Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 118 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

    Scottsdale/Phoenix, AZ

  2. Niraparib + TSR042 In BRCA Mutated Breast Cancer

    Rochester, MN

  3. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  5. A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  6. Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC)

    Albert Lea, MN, Mankato, MN

  8. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

    Rochester, MN

  9. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  10. Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

    Rochester, MN, Jacksonville, FL

.

Mayo Clinic Footer